A promising idea is a starting point for questions. Match the exact treatment and the people studied before deciding how much the finding tells you.
Start with the name and the route.
GHK-Cu is a copper-binding peptide complex. Its name appears in discussions of skin biology and hair research, but a mechanism described in a laboratory is not enough to establish a useful treatment for a patient.
Ask whether the study involved GHK-Cu itself, a related peptide or a mixture. Then check whether the product was applied to skin or injected. Those distinctions are essential when deciding what a result means.
Three research records that are often blurred.
Topical GHK-Cu
A small randomized, vehicle-controlled study involved 18 adults over 12 weeks, comparing a topical GHK-Cu serum with vehicle on opposite eyebrows. The abstract reports improvements in eyebrow hair measures.
The study does not establish scalp-alopecia benefit, injectable efficacy or long-term safety. A small, short study also cannot rule out uncommon or later problems.
Source: Bo and colleagues · 2026 topical GHK-Cu eyebrow study ↗5-ALA plus GHK
A study in 45 men tested a topical combination of 5-aminolevulinic acid and GHK over six months. It studied a combination, not GHK-Cu alone. Its findings cannot isolate the effect of copper peptide or establish an injectable benefit.
Source: Lee and colleagues · 2016 5-ALA plus GHK study ↗AHK-Cu
The often-cited isolated-follicle and cell study concerns AHK-Cu, a different peptide. It is not a patient trial of GHK-Cu. Results from isolated follicles and cells need further study before they can answer a patient’s treatment question.
Source: Pyo and colleagues · 2007 AHK-Cu laboratory study ↗Regulatory status is a separate question.
The FDA’s compounding safety page identifies concerns for injectable GHK-Cu, including potential immune reactions related to aggregation or peptide impurities, and limited human safety data. The wording is specific to the route.
Source: FDA · Compounding substances with potential safety risks ↗Being discussed in compounding policy, sold as a cosmetic or included in a research paper does not establish FDA approval to treat scalp hair loss. Ask your clinician to check the current status of the exact product, route and intended use.
Exosomes: curiosity, with the evidence in view.
Exosomes are tiny cell-derived vesicles studied for their role in communication between cells. That biology makes them interesting to researchers. It does not, by itself, establish that a marketed product safely or effectively treats hair loss.
Products, preparation methods and routes can differ. Ask what was actually tested in people, what benefit was measured, how long it lasted and what safety information is available.
Know the regulatory distinction.
The FDA safety alert states that there are no FDA-approved exosome products and describes serious adverse events associated with unapproved products. This is not simply the same situation as an approved drug being prescribed off-label.
Before considering an experimental treatment, ask about its regulatory status, clinical-trial oversight, known risks and established alternatives. This educational section is not a recommendation to undergo exosome treatment.
FDA · Exosome product safety information ↗Five questions for any promising headline.
- Was this a study in people with the same condition, or in cells or animals?
- Was the exact compound and route tested?
- Was there a suitable comparison group, and how many people participated?
- Was the change meaningful to patients, and how long did it last?
- What adverse effects were measured, and what could a small study miss?
Early evidence can justify further research without supporting a routine treatment recommendation. Compare that uncertainty with the options in the nonsurgical guide.
“What would we need to learn before recommending this for someone with my concern?” That keeps the discussion open while making the uncertainty clear.
Put the research in context.
For hair changes around perimenopause or menopause, begin with the pattern, history and an assessment. A broader health conversation and a hair-treatment claim are different questions.
Women’s hair, hormones and research distinctions →Sources and further reading.
These sources offer further reading. This is not a systematic evidence review, a practice protocol or a complete list of risks.